Video

Dr. Mills on the Shifts Towards Personalized Medicine

Dr. Gordon B. Mills from MD Anderson Cancer Center Discusses Shifts Towards Personalized Medicine

Gordon B. Mills, MD, PhD, chairman, Department of Systems Biology, chief, Section of Molecular Therapeutics, Professor of Medicine and Immunology at the University of Texas MD Anderson Cancer Center, explains that the management of cancer is shifting towards personalized care.

The goal of personalized medicine is to phase out the non-specific chemotherapy approach. Focusing on targeting the specific aberrations can reverse the adverse effects with better efficacy and less toxicity than non-specific chemotherapy.

Paradigms of personalized care already exist for breast cancer. A few examples include the HER2 marker for the use of Herceptin (trastuzumab) and the state of the estrogen receptor (ER) for the use of ER targeted therapies.

Establishing personalized medicine is not without a distinct set of challenges. There is a need to determine the aberrations that can be targeted, likely resistance mechanisms, and lastly how to prevent resistance from occurring.

Related Videos
Marc Machaalani, MD
Craig Eckfeldt, MD, PhD, assistant professor, medicine, faculty, Microbiology, Immunology, and Cancer Biology PhD Graduate Program, Division of Hematology, Oncology, and Transplantation, the University of Minnesota Medical School
Alicia Morgans, MD, MPH, genitourinary medical oncologist, medical director, Survivorship Program, Dana-Farber Cancer Institute; associate professor, medicine, Harvard Medical School
Alfred L. Garfall, MD, MS
Razane El Hajj Chehade, MD
Mark Juckett, MD, professor, medicine, Division of Hematology, Oncology, and Transplantation, the University of Minnesota Medical School
Coral Olazagasti, MD
Barbara Jane O’Brien, MD, associate professor, Neuro-Oncology, Department of Neuro-Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Tycel Phillips, MD
Giuseppe Curigliano, MD, PhD